Clinical Trials Unit
Stanford University School of Medicine's Center for Advanced Dermatologic Investigation is the Dermatology Department's clinical trials unit.
The Center is home to 12-15 ongoing clinical studies, investigating the safety and efficacy of new and currently available drugs and over-the-counter medications. The Center works with Stanford's own panel on medical research, leading pharmaceutical companies,and the Food and Drug Administration to safely and ethically expand the medical field's knowledge of dermatologic treatments. New studies begin regularly, and the Center continues to recruit patients with skin aging, sun damage, skin cancer (including basal cell carcinomas), psoriasis, atopic dermatitis, rosacea, and other dermatologic diseases for ongoing studies.
Skin Aging Studies
We seek to understand the human aging processes as it relates to skin on a fundamental level. To this end, our studies focus on clinical and translational research efforts ranging from: (1) the analysis of gene changes which predispose individuals to exceptionally youthful skin to (2) molecular signatures that may be biomarkers for aging skin to (3) the careful study of new candidate agents which might affect the skin aging process.
Nonmelanoma Skin Cancer
Recent advances in our understanding of basal cell skin cancer biology have enabled the development of cutting edge study drugs which combat tumor growth. We are currently home to a number of clinical trials at the forefront of potential therapy for advanced or metastatic basal cell cancer. In addition, we seek to understand the biology of basal cell skin cancers and to identify molecular predictors for treatment success.
Acne Rosecea
This is a common and frustrating chronic inflammatory condition of the face, usually affecting older individuals. The causes of this complex condition are the subject of much study. Our clinical studies seek to identify new topical or oral medications to improve the symptoms of acne rosacea.
Contact
For more information, please email dermtrials@stanford.edu
Featured Clinical Trials
Targeting the Neurobiology of RRB in Autism Using N-acetylcysteine: Trial
The goal of this study is to target the neurobiology of restricted and repetitive behaviors in children with autism spectrum disorder using N-acetylcysteine (NAC), a well-tolerated nutritional supplement that has shown promise for reducing symptom severity in recent small-scale trials. The findings from this research will shed light on the mechanisms of action underlying the clinical benefits of NAC and the effects of NAC on altering restricted and repetitive behavior symptom severity in children with autism spectrum disorder. This is a 12-week double-blind, randomized, placebo-controlled trial of NAC.
Stanford is currently accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- drug: N acetyl cysteine
- drug: Placebo
Eligibility
Inclusion Criteria:
- children between 3 years and 12 years 11 months
- diagnosis of autism spectrum disorder confirmed with the Autism Diagnostic Interview-
Revised and the Autism Diagnostic Observation Schedule-2, Brief Observation of
Symptoms of Autism, or Childhood Autism Rating Scale
- at least moderate severity of restricted and repetitive behaviors defined by a
Children's Yale-Brown Obsessive Compulsive Scale for Autism Spectrum Disorder score ≥
11
- physical development indicative of prepubescence as defined by criteria for Tanner
Stage 1
- passes MR safety screening (e.g., no metal in the body) and attempts baseline
neuroimaging (MRI or EEG)
- have stable medication regimens (≥ 30 days) and psychosocial treatments (≥ 60 days)
prior to randomization with no anticipated changes during the trial
Exclusion Criteria:
- presence of known genetic abnormalities associated with ASD (e.g. Fragile X)
- current or life-time diagnosis of severe psychiatric disorder (e.g., schizophrenia)
- presence of significant medical problems
- the inability of at least one caregiver to speak and read English to a sufficient
level
- participants taking glutathione agents/prodrugs
- history of any adverse effects to glutathione agents/prodrugs
- the inability to drink a sample study compound dissolved in liquid
Ages Eligible for Study
3 Years - 12 Years
Genders Eligible for Study
All
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Madeleine Clark, BS
(650)736-1235
I'm interested
Psoriasis Clinical Trials
Targeting the Neurobiology of RRB in Autism Using N-acetylcysteine: Trial
The goal of this study is to target the neurobiology of restricted and repetitive behaviors in children with autism spectrum disorder using N-acetylcysteine (NAC), a well-tolerated nutritional supplement that has shown promise for reducing symptom severity in recent small-scale trials. The findings from this research will shed light on the mechanisms of action underlying the clinical benefits of NAC and the effects of NAC on altering restricted and repetitive behavior symptom severity in children with autism spectrum disorder. This is a 12-week double-blind, randomized, placebo-controlled trial of NAC.
Stanford is currently accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- drug: N acetyl cysteine
- drug: Placebo
Eligibility
Inclusion Criteria:
- children between 3 years and 12 years 11 months
- diagnosis of autism spectrum disorder confirmed with the Autism Diagnostic Interview-
Revised and the Autism Diagnostic Observation Schedule-2, Brief Observation of
Symptoms of Autism, or Childhood Autism Rating Scale
- at least moderate severity of restricted and repetitive behaviors defined by a
Children's Yale-Brown Obsessive Compulsive Scale for Autism Spectrum Disorder score ≥
11
- physical development indicative of prepubescence as defined by criteria for Tanner
Stage 1
- passes MR safety screening (e.g., no metal in the body) and attempts baseline
neuroimaging (MRI or EEG)
- have stable medication regimens (≥ 30 days) and psychosocial treatments (≥ 60 days)
prior to randomization with no anticipated changes during the trial
Exclusion Criteria:
- presence of known genetic abnormalities associated with ASD (e.g. Fragile X)
- current or life-time diagnosis of severe psychiatric disorder (e.g., schizophrenia)
- presence of significant medical problems
- the inability of at least one caregiver to speak and read English to a sufficient
level
- participants taking glutathione agents/prodrugs
- history of any adverse effects to glutathione agents/prodrugs
- the inability to drink a sample study compound dissolved in liquid
Ages Eligible for Study
3 Years - 12 Years
Genders Eligible for Study
All
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Madeleine Clark, BS
(650)736-1235
I'm interested
Dermatology Clinical Trials
Targeting the Neurobiology of RRB in Autism Using N-acetylcysteine: Trial
The goal of this study is to target the neurobiology of restricted and repetitive behaviors in children with autism spectrum disorder using N-acetylcysteine (NAC), a well-tolerated nutritional supplement that has shown promise for reducing symptom severity in recent small-scale trials. The findings from this research will shed light on the mechanisms of action underlying the clinical benefits of NAC and the effects of NAC on altering restricted and repetitive behavior symptom severity in children with autism spectrum disorder. This is a 12-week double-blind, randomized, placebo-controlled trial of NAC.
Stanford is currently accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- drug: N acetyl cysteine
- drug: Placebo
Eligibility
Inclusion Criteria:
- children between 3 years and 12 years 11 months
- diagnosis of autism spectrum disorder confirmed with the Autism Diagnostic Interview-
Revised and the Autism Diagnostic Observation Schedule-2, Brief Observation of
Symptoms of Autism, or Childhood Autism Rating Scale
- at least moderate severity of restricted and repetitive behaviors defined by a
Children's Yale-Brown Obsessive Compulsive Scale for Autism Spectrum Disorder score ≥
11
- physical development indicative of prepubescence as defined by criteria for Tanner
Stage 1
- passes MR safety screening (e.g., no metal in the body) and attempts baseline
neuroimaging (MRI or EEG)
- have stable medication regimens (≥ 30 days) and psychosocial treatments (≥ 60 days)
prior to randomization with no anticipated changes during the trial
Exclusion Criteria:
- presence of known genetic abnormalities associated with ASD (e.g. Fragile X)
- current or life-time diagnosis of severe psychiatric disorder (e.g., schizophrenia)
- presence of significant medical problems
- the inability of at least one caregiver to speak and read English to a sufficient
level
- participants taking glutathione agents/prodrugs
- history of any adverse effects to glutathione agents/prodrugs
- the inability to drink a sample study compound dissolved in liquid
Ages Eligible for Study
3 Years - 12 Years
Genders Eligible for Study
All
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Madeleine Clark, BS
(650)736-1235
I'm interested
Pediatric Dermatology Clinical Trials
Targeting the Neurobiology of RRB in Autism Using N-acetylcysteine: Trial
The goal of this study is to target the neurobiology of restricted and repetitive behaviors in children with autism spectrum disorder using N-acetylcysteine (NAC), a well-tolerated nutritional supplement that has shown promise for reducing symptom severity in recent small-scale trials. The findings from this research will shed light on the mechanisms of action underlying the clinical benefits of NAC and the effects of NAC on altering restricted and repetitive behavior symptom severity in children with autism spectrum disorder. This is a 12-week double-blind, randomized, placebo-controlled trial of NAC.
Stanford is currently accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- drug: N acetyl cysteine
- drug: Placebo
Eligibility
Inclusion Criteria:
- children between 3 years and 12 years 11 months
- diagnosis of autism spectrum disorder confirmed with the Autism Diagnostic Interview-
Revised and the Autism Diagnostic Observation Schedule-2, Brief Observation of
Symptoms of Autism, or Childhood Autism Rating Scale
- at least moderate severity of restricted and repetitive behaviors defined by a
Children's Yale-Brown Obsessive Compulsive Scale for Autism Spectrum Disorder score ≥
11
- physical development indicative of prepubescence as defined by criteria for Tanner
Stage 1
- passes MR safety screening (e.g., no metal in the body) and attempts baseline
neuroimaging (MRI or EEG)
- have stable medication regimens (≥ 30 days) and psychosocial treatments (≥ 60 days)
prior to randomization with no anticipated changes during the trial
Exclusion Criteria:
- presence of known genetic abnormalities associated with ASD (e.g. Fragile X)
- current or life-time diagnosis of severe psychiatric disorder (e.g., schizophrenia)
- presence of significant medical problems
- the inability of at least one caregiver to speak and read English to a sufficient
level
- participants taking glutathione agents/prodrugs
- history of any adverse effects to glutathione agents/prodrugs
- the inability to drink a sample study compound dissolved in liquid
Ages Eligible for Study
3 Years - 12 Years
Genders Eligible for Study
All
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Madeleine Clark, BS
(650)736-1235
I'm interested
Targeting the Neurobiology of RRB in Autism Using N-acetylcysteine: Trial
The goal of this study is to target the neurobiology of restricted and repetitive behaviors in children with autism spectrum disorder using N-acetylcysteine (NAC), a well-tolerated nutritional supplement that has shown promise for reducing symptom severity in recent small-scale trials. The findings from this research will shed light on the mechanisms of action underlying the clinical benefits of NAC and the effects of NAC on altering restricted and repetitive behavior symptom severity in children with autism spectrum disorder. This is a 12-week double-blind, randomized, placebo-controlled trial of NAC.
Stanford is currently accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- drug: N acetyl cysteine
- drug: Placebo
Eligibility
Inclusion Criteria:
- children between 3 years and 12 years 11 months
- diagnosis of autism spectrum disorder confirmed with the Autism Diagnostic Interview-
Revised and the Autism Diagnostic Observation Schedule-2, Brief Observation of
Symptoms of Autism, or Childhood Autism Rating Scale
- at least moderate severity of restricted and repetitive behaviors defined by a
Children's Yale-Brown Obsessive Compulsive Scale for Autism Spectrum Disorder score ≥
11
- physical development indicative of prepubescence as defined by criteria for Tanner
Stage 1
- passes MR safety screening (e.g., no metal in the body) and attempts baseline
neuroimaging (MRI or EEG)
- have stable medication regimens (≥ 30 days) and psychosocial treatments (≥ 60 days)
prior to randomization with no anticipated changes during the trial
Exclusion Criteria:
- presence of known genetic abnormalities associated with ASD (e.g. Fragile X)
- current or life-time diagnosis of severe psychiatric disorder (e.g., schizophrenia)
- presence of significant medical problems
- the inability of at least one caregiver to speak and read English to a sufficient
level
- participants taking glutathione agents/prodrugs
- history of any adverse effects to glutathione agents/prodrugs
- the inability to drink a sample study compound dissolved in liquid
Ages Eligible for Study
3 Years - 12 Years
Genders Eligible for Study
All
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Madeleine Clark, BS
(650)736-1235
I'm interested
Targeting the Neurobiology of RRB in Autism Using N-acetylcysteine: Trial
The goal of this study is to target the neurobiology of restricted and repetitive behaviors in children with autism spectrum disorder using N-acetylcysteine (NAC), a well-tolerated nutritional supplement that has shown promise for reducing symptom severity in recent small-scale trials. The findings from this research will shed light on the mechanisms of action underlying the clinical benefits of NAC and the effects of NAC on altering restricted and repetitive behavior symptom severity in children with autism spectrum disorder. This is a 12-week double-blind, randomized, placebo-controlled trial of NAC.
Stanford is currently accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- drug: N acetyl cysteine
- drug: Placebo
Eligibility
Inclusion Criteria:
- children between 3 years and 12 years 11 months
- diagnosis of autism spectrum disorder confirmed with the Autism Diagnostic Interview-
Revised and the Autism Diagnostic Observation Schedule-2, Brief Observation of
Symptoms of Autism, or Childhood Autism Rating Scale
- at least moderate severity of restricted and repetitive behaviors defined by a
Children's Yale-Brown Obsessive Compulsive Scale for Autism Spectrum Disorder score ≥
11
- physical development indicative of prepubescence as defined by criteria for Tanner
Stage 1
- passes MR safety screening (e.g., no metal in the body) and attempts baseline
neuroimaging (MRI or EEG)
- have stable medication regimens (≥ 30 days) and psychosocial treatments (≥ 60 days)
prior to randomization with no anticipated changes during the trial
Exclusion Criteria:
- presence of known genetic abnormalities associated with ASD (e.g. Fragile X)
- current or life-time diagnosis of severe psychiatric disorder (e.g., schizophrenia)
- presence of significant medical problems
- the inability of at least one caregiver to speak and read English to a sufficient
level
- participants taking glutathione agents/prodrugs
- history of any adverse effects to glutathione agents/prodrugs
- the inability to drink a sample study compound dissolved in liquid
Ages Eligible for Study
3 Years - 12 Years
Genders Eligible for Study
All
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Madeleine Clark, BS
(650)736-1235
I'm interested